The Lancet Rheumatology in conversation with

Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.

Listen on:

  • Podbean App

Episodes

Friday Jun 20, 2025

This is a joint podcast between The Lancet Rheumatology and The Lancet Regional Health - Western Pacific with Prof Xue Li. Biologics have become a mainstay of treatment in Rheumatology in Western populations, but in many parts of Asia, especially lower-and-middle-income countries, there remains substantial inequity in access due to differences in availability and affordability.In this episode, we explore the factors that may have delayed the popularisation of biologics in Asia, any recent policy changes and the role of biosimilars in this landscape.Read the full article:https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(22)00121-3/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanwpcContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Jun 16, 2025

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Tuesday Jun 03, 2025

This is the third and final episode of our mini-series on cell-based therapies in rheumatology, with Professor Fabian Müller and Dr Melanie Hagen from the Erlangen University, Germany. We discuss their recently published a study on a newly discovered toxicity of CD-19 targeting CAR T-cell therapy in patients with autoimmune disease, as well as the recent successes of CAR T-cell therapy, ideal patient selection, and future directions.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00091-8/fulltext?dgcid=buzzsprout_icw_podcast_Jun_25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Friday Apr 25, 2025

This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE). We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the future for this area of research. You can find the study here:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00298-4/fulltext?dgcid=buzzsprout_icw_podcast_25-04-25_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Mar 24, 2025

The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Feb 24, 2025

Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Jan 27, 2025

Dr Brooke Conley and Associate Professor Ivan Lin discuss their recent study on integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Dec 23, 2024

Dr Mark Russell and Sherry Yang discuss the factors influencing initiation of biologics in underserved populations with rheumatoid arthritis in the UK, how historical redlining and present-day racialised economic segregation affects health-care utilisation of adults with rheumatic diseases in the USA, and health inequities seen in rheumatology more broadly.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00221-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Nov 25, 2024

Dr Quirine Dumoulin discusses the efficacy of a 1-year course of methotrexate on the development of rheumatoid arthritis in ACPA-negative people with clinically suspect arthralgia and predicted increased risk of rheumatoid arthritis.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00196-6?dgcid=buzzsprout_icw_podcast_generic_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Monday Oct 21, 2024

Dr Sebastian Sattui discusses the effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Read the full article:https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00193-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrheContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

© 2026 The Lancet Group

Podcast Powered By Podbean

Version: 20241125